Cited 4 time in
Regioselective synthesis and molecular docking studies of functionalized imidazo [1,2-a]pyridine derivatives through MCRs
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Yadav, Maruti B. | - |
| dc.contributor.author | Singh, Pooja | - |
| dc.contributor.author | Jeong, Yeon Tae | - |
| dc.date.accessioned | 2023-06-28T09:40:59Z | - |
| dc.date.available | 2023-06-28T09:40:59Z | - |
| dc.date.issued | 2024-02 | - |
| dc.identifier.issn | 1381-1991 | - |
| dc.identifier.issn | 1573-501X | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/59705 | - |
| dc.description.abstract | A efficient protocol has been developed for the synthesis of regioselective imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine derivatives through cascade reaction between 2-aminopyridine, arylelglyoxal, and 4-hydroxypyran via three-component reaction to prepare targeted compounds with good to excellent yields. The advantages of this transformation are a catalyst-free reaction, green solvent, operationally simple, scalable, and eco-friendly. The product collects with simple filtration which avoided tedious and expensive purification techniques. In addition, computational studies like molecular docking were conducted to provide the theoretical possibilities of binding these types of synthesized compounds to the VEGFR2 receptors as potential key inhibitors of tumor cell growth and angiogenesis. © 2023, The Author(s), under exclusive licence to Springer Nature Switzerland AG. | - |
| dc.format.extent | 12 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Institute for Ionics | - |
| dc.title | Regioselective synthesis and molecular docking studies of functionalized imidazo [1,2-a]pyridine derivatives through MCRs | - |
| dc.type | Article | - |
| dc.publisher.location | 네델란드 | - |
| dc.identifier.doi | 10.1007/s11030-023-10669-9 | - |
| dc.identifier.scopusid | 2-s2.0-85162018562 | - |
| dc.identifier.wosid | 001010692600001 | - |
| dc.identifier.bibliographicCitation | Molecular Diversity, v.28, no.1, pp 171 - 182 | - |
| dc.citation.title | Molecular Diversity | - |
| dc.citation.volume | 28 | - |
| dc.citation.number | 1 | - |
| dc.citation.startPage | 171 | - |
| dc.citation.endPage | 182 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
| dc.relation.journalResearchArea | Chemistry | - |
| dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
| dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
| dc.relation.journalWebOfScienceCategory | Chemistry, Applied | - |
| dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
| dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
| dc.subject.keywordPlus | ONE-POT | - |
| dc.subject.keywordPlus | 3-COMPONENT REACTION | - |
| dc.subject.keywordPlus | ANNULATED PYRIDINES | - |
| dc.subject.keywordPlus | INHIBITORS | - |
| dc.subject.keywordPlus | PYRAZINES | - |
| dc.subject.keywordPlus | ACCESS | - |
| dc.subject.keywordPlus | CYCLIZATION | - |
| dc.subject.keywordPlus | BINDING | - |
| dc.subject.keywordPlus | TARGET | - |
| dc.subject.keywordPlus | ARYL | - |
| dc.subject.keywordAuthor | Imidazo[1,2-a]pyrimidine | - |
| dc.subject.keywordAuthor | Knoevenagel condensation | - |
| dc.subject.keywordAuthor | Michael adduct | - |
| dc.subject.keywordAuthor | Molecular docking | - |
| dc.subject.keywordAuthor | Regioselectivity | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
